The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype

@article{Croonquist2005ThePG,
  title={The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype},
  author={Paula A Croonquist and Brian Van Ness},
  journal={Oncogene},
  year={2005},
  volume={24},
  pages={6269-6280}
}
Three distinct proliferative signals for multiple myeloma (MM) cell lines induce enhancer of zeste homolog 2 (ezh2) transcript expression. EZH2 is a polycomb group protein that mediates repression of gene transcription at the chromatin level through its methyltransferase activity. Normal bone marrow plasma cells do not express ezh2; however, gene expression is induced and correlates with tumor burden during progression of this disease. We therefore investigated how EZH2 expression is… Expand
Polycomb Group Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell Line
TLDR
This study marks the first demonstration of neoplastic transformation in prostate cells mediated by EZh2 and establishes that EZH2 possesses stronger transforming activity than Akt but weaker activity than activated Ras. Expand
PolycombGroup Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell Line
Polycomb group protein enhancer of zeste 2 (EZH2) is a master regulatory protein that plays a critical role in development as part of the polycomb repressive complex 2. Polycomb repressive complex 2Expand
Enhancer of zeste homolog 2 overexpression in nasopharyngeal carcinoma: an independent poor prognosticator that enhances cell growth.
TLDR
At least partly through promoting cell growth, EZH2 implicates disease progression, confers tumor aggressiveness, and represents an independent adverse prognosticator in patients with NPC. Expand
Targeting EZH 2 in Multiple Myeloma — Multifaceted Anti-Tumor Activity
The enhancer of zeste homolog 2 (EZH2) is the enzymatic subunit of the polycomb repressive complex 2 (PRC2) that exerts important functions during normal development as well as disease. PRC2 throughExpand
Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
TLDR
The possibility that EZH2 inhibitors could be a useful therapeutic modality in MM alone or in combination with other targeted agents in MM is raised. Expand
The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells
TLDR
It is indicated that the EZH2 gene plays a role for both the proliferation and the apoptosis resistance of RCC cells, and could represent a novel strategy to improve the therapeutic response of R CC. Expand
The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer
TLDR
The data show that amplification of the EZH2 gene is rare in early prostate cancer, whereas a fraction of late‐stage tumors contains the gene amplification leading to the overexpression of the gene, thus indicating the importance of EZh2 in the progression of prostate cancer. Expand
Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells in vitro
TLDR
The results showed that EZH2 protein is overexpressed in the pediatric monocytic cell-line THP-1, but not in other leukemia-derived cell lines MV4;11 and SEM, which provides initial evidence that targeting EZh2 is a promising therapeutic strategy for the treatment of subtypes of pediatric AML. Expand
EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
TLDR
It is demonstrated that EZH2 inhibition causes a global reduction of H3K27me3 in multiple myeloma cells, promoting reexpression of EZh2-repressed tumor suppressor genes in a subset of cell lines, and the antitumor efficacy of EzH2 inhibitors is confirmed in vivo in a multipleMyeloma xenograft model in mice. Expand
Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein.
TLDR
It is concluded that the E7 target gene EZH2 is a major determinant for the proliferation of HPV-positive cancer cells and contributes to their apoptotic resistance, and may serve as a novel therapeutic target for the treatment of cervical cancer. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma
TLDR
This is the first demonstration that EZH2 expression can be upregulated in fresh lymphoma cells and suggests a possible causal effect between EZh2 upregulation and increased proliferation in haematopoietic cells. Expand
The polycomb group protein EZH2 is involved in progression of prostate cancer
TLDR
Dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression. Expand
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
  • C. Kleer, Q. Cao, +12 authors A. Chinnaiyan
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2003
TLDR
Tissue microarray analysis demonstrated that EZH2 protein levels were strongly associated with breast cancer aggressiveness and provided compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation. Expand
Proliferative involvement of ENX‐1, a putative human Polycomb group gene, in haematopoietic cells
TLDR
The data indicate that ENX‐1 is involved in the proliferation of both normal and malignant haematopoietic cells. Expand
Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.
TLDR
Model cell lines show that changes in ras or p53 can alter the myeloma cell response to IL-6 and demonstrate that the genetic background can alter therapeutic responses. Expand
Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex
TLDR
This work purified an ESC-E(Z) complex from Drosophila embryos and found four major subunits: ESC, E(Z), NURF-55, and the PcG repressor, SU( Z)12, which methylates lysine-27 of histone H3. Expand
Gene profiling of a myeloma cell line reveals similarities and unique signatures among IL-6 response, N-ras-activating mutations, and coculture with bone marrow stromal cells.
ANBL-6, a myeloma cell line, proliferates in response to interleukin 6 (IL-6) stimulation, coculture with bone marrow stromal cells, and when harboring a constitutively active mutant N-ras gene.Expand
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
TLDR
The purification and characterization of an EED-EZH2 complex, the human counterpart of the Drosophila ESC-E(Z) complex, is reported, and it is demonstrated that the complex specifically methylates nucleosomal histone H3 at lysine 27 (H3-K27). Expand
Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells
TLDR
The data show a very distinct IL-6 signal transduction and kinetics in these cell lines and the distinct molecular events correlate closely to the cell fate of the lymphoblast and myeloma cell lines. Expand
Identification and Characterization of a Novel Androgen Receptor Coregulator ARA267-α in Prostate Cancer Cells*
TLDR
The isolation of a new AR coregulator with a calculated molecular mass of 267 kDa named the androgen receptor-associated protein 267-α (ARA267-α) is reported, containing the SET domain with an exceptionally large molecular mass that can enhance AR transactivation in prostate cancer cells. Expand
...
1
2
3
...